IMUX · Immunic, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $25.63M | - | $20.01M | $21.37M | $21.53M | - | $21.37M | $18.32M | $18.74M | - |
| SG&A | $7.61M | - | $5.98M | $5.71M | $5.29M | - | $4.36M | $4.49M | $5.14M | - |
| Total Operating Expenses | $33.23M | - | $25.99M | $27.08M | $26.82M | - | $25.73M | $22.81M | $23.88M | - |
| D&A | $33.0K | - | $42.0K | $31.0K | $43.0K | - | $42.0K | $31.0K | $26.0K | - |
| Operating Income | ($33.23M) | - | ($25.99M) | ($27.08M) | ($26.82M) | - | ($25.73M) | ($22.81M) | ($23.88M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($32.59M) | - | ($25.58M) | ($26.82M) | ($25.47M) | - | ($24.37M) | ($21.38M) | ($29.58M) | - |
| EPS - Basic | ($1.08) | - | ($1.30) | ($2.00) | ($2.50) | - | ($2.40) | ($2.10) | ($3.00) | - |
| EPS - Diluted | ($1.08) | - | ($1.30) | ($2.00) | ($2.50) | - | ($2.40) | ($2.10) | ($3.00) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $186.63M | $15.48M | $35.13M | $55.31M | $14.30M | $35.67M | $59.07M | $79.70M | $97.31M | $46.67M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $11.01M | $10.14M | $7.92M | $7.89M | $6.01M | $7.85M | $6.04M | $7.89M | $6.77M | $5.10M |
| Current Assets | $188.76M | $22.87M | $39.27M | $59.84M | $18.98M | $39.33M | $63.27M | $84.98M | $102.61M | $52.53M |
| Total Assets | $189.74M | $24.05M | $40.70M | $61.43M | $20.52M | $40.87M | $64.76M | $86.49M | $104.16M | $54.30M |
| Current Liabilities | $38.36M | $30.62M | $30.08M | $27.31M | $25.59M | $22.18M | $23.36M | $22.68M | $20.15M | $24.73M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $38.51M | $30.73M | $30.20M | $27.52M | $25.80M | $22.44M | $23.54M | $22.92M | $20.58M | $25.37M |
| Stockholders' Equity | $151.23M | ($6.67M) | $10.50M | $33.91M | ($5.29M) | $18.43M | $41.22M | $63.57M | $83.58M | $28.93M |
| Retained Earnings | ($641.16M) | ($608.57M) | ($589.27M) | ($563.69M) | ($536.87M) | ($511.40M) | ($486.22M) | ($461.86M) | ($440.48M) | ($410.89M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($17.30M) | - | - | - | ($21.78M) | - | - | - | ($23.97M) | - |
| Investing Cash Flow | ($2.0K) | - | - | - | ($47.0K) | - | - | - | ($31.0K) | - |
| Financing Cash Flow | $188.64M | - | - | - | $0 | - | - | - | $74.46M | - |
| CapEx | $2.0K | - | - | - | $47.0K | - | - | - | $31.0K | - |
| Free Cash Flow | ($17.30M) | - | - | - | ($21.82M) | - | - | - | ($24.00M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | 0.53 | - | - | - | 0.86 | - | - | - | 0.81 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -17.2% | - | -62.8% | -43.7% | -124.2% | - | -37.6% | -24.7% | -28.4% | - |
| Return on equity | -21.5% | - | -243.6% | -79.1% | 481.8% | - | -59.1% | -33.6% | -35.4% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 4.92 | 0.75 | 1.31 | 2.19 | 0.74 | 1.77 | 2.71 | 3.75 | 5.09 | 2.12 |
| Quick ratio | 4.92 | 0.75 | 1.31 | 2.19 | 0.74 | 1.77 | 2.71 | 3.75 | 5.09 | 2.12 |
| Cash ratio | 4.86 | 0.51 | 1.17 | 2.03 | 0.56 | 1.61 | 2.53 | 3.51 | 4.83 | 1.89 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.25 | -3.60 | 3.88 | 1.81 | -3.88 | 2.22 | 1.57 | 1.36 | 1.25 | 1.88 |
| Liabilities / Assets | 0.20 | 1.28 | 0.74 | 0.45 | 1.26 | 0.55 | 0.36 | 0.26 | 0.20 | 0.47 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 2.2x | - | 162.9x | 27.2x | - | - | 40.5x | 17.7x | 15.4x | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -23.9% | - | -1.0% | -18.7% | -12.3% | - | -9.1% | 8.8% | 12.4% | - |
| Net income growth (YoY) | -27.9% | - | -5.0% | -25.4% | 13.9% | - | -7.0% | 10.9% | -17.1% | - |
| EPS growth (YoY) | 56.8% | - | 45.8% | 4.8% | 16.7% | - | -370.6% | -288.9% | -417.2% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | 20.7% | - | - | - | 9.1% | - | - | - | -22.3% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | - | - | -74.5% | -46.7% | - | -36.3% | -14.8% | -8.2% | -8.4% | -74.6% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing IMMUNIC against the 5 most active filers in the same SIC group.